Hua Medicine (“Hua” or the “Company”, Stock Code: 2552.HK), as a pre-revenue drug development company, today announced its interim results for the six months ended June 30, 2019 (the “Review Period”).
At last week’s American Diabetes Association’s 79th Scientific Sessions, Hua Medicine, a Shanghai-based drug development company focused on developing a global first-in-class oral drug for the treatment of Type 2 diabetes
Hua Medicine (HKEX: 2552), announced today our updated pipeline regarding our core technology targeting glucose homeostasis and first product, a glucokinase activator dorzagliatin (HMS5552).
The trial is a pharmacokinetic and pharmacodynamic study of dorzagliatin in combination with empagliflozin to investigate the PK/PD of each drug alone or in combination.
Hua Medicine (the “Company”, Stock Code: 2552.HK) today announced its consolidated results for the year ended December 31, 2018 (the “Review Period”). As of December 31, 2018, the Company’s cash position was approximately RMB 1,443.3 million.
Hua Medicine (HKEX: 2552), a Shanghai-based drug development company focused on developing a global first-in-class oral drug for the treatment of Type 2 diabetes, announced today the completion of patient enrollment for a Phase III monotherapy trial of HMS5552 (dorzagliatin). Hua Medicine therefore expects to release the topline results in 4th quarter of 2019.
Copyright © 2019 Hua Medicine, All Rights Reserved沪ICP备14036654号